| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | Chief Research and Development | Common Stock | 61.8K | $1.17M | $18.95 | 26 Aug 2025 | Direct |
| Apellis Pharmaceuticals, Inc. | Chief Research and Development | Stock Option (Right to Buy) | 92.6K | 26 Aug 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals, Inc. | 26 Aug 2025 | 2 | $0 | 4 | Chief Research and Development | 02 Sep 2025, 10:13 |
| APLS | Apellis Pharmaceuticals, Inc. | 26 Aug 2025 | 0 | $0 | 3 | Chief Research and Development | 02 Sep 2025, 10:12 |